- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2011–2021 · research · R01
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2028 · program · P01
Integrative Oncogenomics of Multiple Myeloma
Nikhil C. Munshi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2022 · program · P01
Integrative Oncogenomics of Multiple Myeloma
Nikhil C. Munshi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2023 · program · P01
Integrative Oncogenomics of Multiple Myeloma
Nikhil C. Munshi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2028 · program · P01
Integrative Oncogenomics of Multiple Myeloma
Nikhil C. Munshi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2027 · research · R01
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2028 · program · P01
Integrative Oncogenomics of Multiple Myeloma
Nikhil C. Munshi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2023 · program · P01
Project 3. Oncogenomics to identify and validate novel targeted therapies in myeloma
Kenneth C. Anderson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2028 · program · P01
Core 1: Administrative Core
Nikhil C. Munshi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2023 · program · P01
Project 2. Investigating epigenetic circuitry in multiple myeloma
Richard Young · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2023 · program · P01
Core 5: Biostatistics and Bioinformatics
Giovanni Luigi Parmigiani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2023 · program · P01
Core 1: Administrative and Communication Core
Nikhil C. Munshi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2028 · program · P01
Core 5 - Biostatistics and Bioinformatics Core
Giovanni Luigi Parmigiani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2023 · program · P01
Core 4: Genome Sequencing Core
Peter Campbell · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2023 · program · P01
Core 2: Clinical and Tissue Core
Herve Avet Loiseau · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2023 · program · P01
Project 1. Developing MRD-based therapeutic strategy in newly-diagnosed multiple myeloma
Herve Avet Loiseau · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2028 · program · P01
Core 4 - Genome Sequencing Core
Mehmet Kemal Samur · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2028 · program · P01
Core 3 - Epigenomics Core
Charles B Epstein · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2023 · program · P01
Project 4. Targeting genomic instability and evolution in myeloma
Nikhil C. Munshi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2023 · program · P01
Core 3: Epigenomics Core
Charles B Epstein · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2028 · program · P01
Project 2: Investigating regulation of transcriptional condensates in multiple myeloma
Richard Young · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2028 · program · P01
Project 4: Targeting genomic instability and evolution in myeloma
Nikhil C. Munshi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2028 · program · P01
Project 1: Developing MRD-based therapeutic strategy in newly diagnosed multiple myeloma
Jill Corre · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2028 · program · P01
Project 3: Defining the biologic role and therapeutic implications of lncRNA in multiple myeloma
Kenneth C. Anderson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2011–2028 · program · P01
Core 2 - Clinical and Tissue Core
Jill Corre · Dana-Farber Cancer Institute · funded by National Institutes of Health
2010–2021 · research · R01
CRLF2 signaling in B-cell acute lymphoblastic leukemia
David Marc Weinstock · Dana-Farber Cancer Institute · funded by National Institutes of Health
2010–2020 · research · R01
Molecular mechanism and relevance of microRNAs in DSB repair pathway choice
Dipanjan Chowdhury · Dana-Farber Cancer Institute · funded by National Institutes of Health
2010–2021 · research · R01
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2010–2020 · research · R01
Molecular mechanism and relevance of microRNAs in DSB repair pathway choice
Dipanjan Chowdhury · Dana-Farber Cancer Institute · funded by National Institutes of Health
2010–2023 · research · R01
Regulation of intestinal genes by CDX2 and other tissue-restricted transcription factors
Ramesh A Shivdasani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2010–2021 · research · R01
CRLF2 signaling in B-cell acute lymphoblastic leukemia
David Marc Weinstock · Dana-Farber Cancer Institute · funded by National Institutes of Health
2010–2026 · cooperative agreement · U54
2/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research
Gregory Alan Abel · Dana-Farber Cancer Institute · funded by National Institutes of Health
2010–2022 · research · R01
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2010–2022 · research · R01
Regulation of intestinal genes by CDX2 and other tissue-restricted transcription factors
Ramesh A Shivdasani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2010–2026 · cooperative agreement · U54
2/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research
Gregory Alan Abel · Dana-Farber Cancer Institute · funded by National Institutes of Health
2010–2020 · research · R01
Molecular mechanism and relevance of microRNAs in DSB repair pathway choice
Dipanjan Chowdhury · Dana-Farber Cancer Institute · funded by National Institutes of Health
2010–2021 · research · R01
CRLF2 signaling in B-cell acute lymphoblastic leukemia
David Marc Weinstock · Dana-Farber Cancer Institute · funded by National Institutes of Health
2010–2022 · research · R01
Regulation of intestinal genes by CDX2 and other tissue-restricted transcription factors
Ramesh A Shivdasani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2010–2021 · cooperative agreement · U54
2/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research
Kasisomayajula Viswanath · Dana-Farber Cancer Institute · funded by National Institutes of Health
2010–2020 · research · R01
CRLF2 signaling in B-cell acute lymphoblastic leukemia
David Marc Weinstock · Dana-Farber Cancer Institute · funded by National Institutes of Health
